Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials is interpreted.

Variation in PICU mortality by ethnicity and area-level deprivation highlights the importance of further investigation into ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...